FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis

An 80-year-old man with metastatic melanoma had been receiving treatment with pembrolizumab from September 2015 until June 2017. Series FDG PET/CT scans from March 7, 2017, to June 14, 2018, showed the course of biopsy-proven pembrolizumab-induced sarcoidosis. Reported here is the first case of multiorgan sarcoidosis induced by pembrolizumab and its self-resolving course on FDG PET/CT. Received for publication September 23, 2018; revision accepted October 20, 2018. Conflict of interest and sources of funding: none declared. Correspondence to: Yang Lu, MD, PhD, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler, Unit 1483, Houston, TX 77030. E-mail: ylu10@mdanderson.org. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

from A via a.sfakia on Inoreader https://ift.tt/2EsPD4u